A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses

The development of broad-spectrum coronavirus vaccines is essential to prepare for future respiratory virus pandemics. We demonstrated broad neutralization by a trivalent subunit vaccine, formulating the receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 XBB.1.5 with Alum and CpG55.2. Vaccinated mice produced cross-neutralizing antibodies against all three human Betacoronaviruses and others currently exclusive to bats, indicating the epitope preservation of the individual antigens during co-formulation and the potential for epitope broadening.

Type

Journal article

Citation

Thimmiraju, S. R., Adhikari, R., Redd, J. R., Villar, M. J., Lee, J., Liu, Z., Chen, Y.-L., Sharma, S., Kaur, A., Uzcategui, N. L., Ronca, S. E., Chen, W.-H., Kimata, J. T., Zhan, B., Strych, U., Bottazzi, M. E., Hotez, P. J., & Pollet, J. (2024). A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. Npj Vaccines, 9(1), 1–5. https://doi.org/10.1038/s41541-024-00924-x

Published Version

https://doi.org/10.1038/s41541-024-00924-x

Rights

Except where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license. Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.